{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T17:05:15Z","timestamp":1744736715583},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T00:00:00Z","timestamp":1629158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Anovulation is one of the common causes of infertility. Polycystic ovary syndrome (PCOS) is the most common disorder with chronic Anovulation. To the best of our knowledge, insulin resistance relates significantly to PCOS. Therefore administration of insulin-sensitizing drugs such as pioglitazone can be used for ovulation stimulation in PCO patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>After obtaining approval from the Ethics Committee of Mashhad University of Medical Sciences, 61 patients with PCOS were enrolled in the study based on inclusion\/ exclusion criteria. Patients were divided into two groups. The first group received 30\u00a0mg (mg) of pioglitazone daily from the second day of the menstrual period. The second one received a placebo. 150\u00a0mg clomiphene citrate was administered from the third to the seventh day of the menstrual cycle. Vaginal sonography was performed in all women, and in cases with the mature follicle, intrauterine insemination was conducted after human chorionic gonadotropin injection. Ovary stimulation and pregnancy rate were compared between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There were no differences between groups regard to demographic characteristics and infertility type. Body mass index was higher in the pioglitazone group (28.3\u2009\u00b1\u20093.8 versus 26.2\u2009\u00b1\u20093.5, <jats:italic>P<\/jats:italic> value\u2009=\u20090.047). The size of the follicle was not significantly different between groups (2.2\u2009\u00b1\u20091.4 versus 1.3\u2009\u00b1\u20091.1, <jats:italic>P<\/jats:italic> value\u2009=\u20090.742). pregnancy rate [4 (12.9%) versus 4 (13.3%), <jats:italic>P<\/jats:italic> value\u2009=\u20091] had no differences between groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Although the number of follicles was higher in the pioglitazone group, our study showed no differences in ovary stimulation and pregnancy rate.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-021-01448-5","type":"journal-article","created":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T09:02:52Z","timestamp":1629190972000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Combination of pioglitazone and clomiphene citrate versus clomiphene citrate alone for infertile women with the polycystic ovarian syndrome"],"prefix":"10.1186","volume":"21","author":[{"given":"Maliheh","family":"Amirian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sedigheh","family":"Shariat Moghani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faezeh","family":"Jafarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masoumeh","family":"Mirteimouri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shima","family":"Nikdoust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabnam","family":"Niroumand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Salehi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aryan","family":"Payrovnaziri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,17]]},"reference":[{"issue":"12","key":"1448_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ogrm.2012.10.003","volume":"22","author":"S Kini","year":"2012","unstructured":"Kini S. Polycystic ovary syndrome: diagnosis and management of related infertility. Obstet Gynaecol Reprod Med. 2012;22(12):347\u201353.","journal-title":"Obstet Gynaecol Reprod Med"},{"issue":"1","key":"1448_CR2","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1056\/NEJMcp1514916","volume":"375","author":"CR McCartney","year":"2016","unstructured":"McCartney CR, Marshall JC. Polycystic ovary syndrome. New Engl J Med. 2016;375(1):54\u201364. https:\/\/doi.org\/10.1056\/NEJMcp1514916.","journal-title":"New Engl J Med"},{"key":"1448_CR3","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.4103\/jfmpc.jfmpc_646_19","volume":"8","author":"IA Abdelazim","year":"2019","unstructured":"Abdelazim IA, Kanshaiym S. Abdelazim and Sakiye endocrinopathy associated with polycystic ovary syndrome: case reports. J Fam Med Prim Care. 2019;8:3039\u201341.","journal-title":"J Fam Med Prim Care"},{"issue":"2","key":"1448_CR4","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.fertnstert.2008.06.045","volume":"92","author":"KA Toulis","year":"2009","unstructured":"Toulis KA, Goulis DG, Kolibianakis EM, Venetis CA, Tarlatzis BC, Papadimas I. Risk of gestational diabetes mellitus in women with polycystic ovary syndrome: a systematic review and a meta-analysis. Fertil Steril. 2009;92(2):667\u201377.","journal-title":"Fertil Steril"},{"issue":"2","key":"1448_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.fertnstert.2009.06.025","volume":"94","author":"M Pall","year":"2010","unstructured":"Pall M, Azziz R, Beires J, Pignatelli D. The phenotype of hirsute women: a comparison of polycystic ovary syndrome and 21-hydroxylase\u2013deficient nonclassic adrenal hyperplasia. Fertil Steril. 2010;94(2):684\u20139.","journal-title":"Fertil Steril"},{"issue":"6","key":"1448_CR6","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1016\/j.fertnstert.2008.09.018","volume":"92","author":"LJ Moran","year":"2009","unstructured":"Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92(6):1966\u201382.","journal-title":"Fertil Steril"},{"issue":"2","key":"1448_CR7","doi-asserted-by":"publisher","first-page":"00008","DOI":"10.15406\/mojwh.2015.01.00008","volume":"1","author":"R Mostafa","year":"2015","unstructured":"Mostafa R, Al-Sherbeeny MM, Abdelazim IA, Elshehawy Y, Wahba KA, Abuel-Fadle A. Frequency of insulin resistance in Egyptian women with polycystic ovary syndrome. MOJ Womens Health. 2015;1(2):00008. https:\/\/doi.org\/10.15406\/mojwh.2015.01.00008.","journal-title":"MOJ Womens Health"},{"issue":"4","key":"1448_CR8","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s00404-017-4480-z","volume":"296","author":"Y Xu","year":"2017","unstructured":"Xu Y, Wu Y, Huang Q. Comparison of the effect between pioglitazone and metformin in treating patients with PCOS: a meta-analysis. Arch Gynecol Obstet. 2017;296(4):661\u201377. https:\/\/doi.org\/10.1007\/s00404-017-4480-z.","journal-title":"Arch Gynecol Obstet"},{"issue":"1","key":"1448_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13048-018-0395-y","volume":"11","author":"M Morishita","year":"2018","unstructured":"Morishita M, Endo T, Baba T, Kuno Y, Ikeda K, Kiya T, et al. pioglitazone is effective for multiple phenotypes of the Zuckerfa\/fa rat with polycystic ovary morphology and insulin resistance. J Ovarian Res. 2018;11(1):24. https:\/\/doi.org\/10.1186\/s13048-018-0395-y.","journal-title":"J Ovarian Res"},{"issue":"2","key":"1448_CR10","doi-asserted-by":"publisher","first-page":"00008","DOI":"10.15406\/mojwh.2015.01.00008","volume":"1","author":"R Mostafa","year":"2015","unstructured":"Mostafa R, Al-Sherbeeny MM, Abdelazim IA, Elshehawy Y, Wahba KA, Abuel-Fadle A. Frequency of insulin resistance in Egyptian women with polycystic ovary syndrome. MOJ Women\u2019s Health. 2015;1(2):00008. https:\/\/doi.org\/10.15406\/mojwh.2015.01.00008.","journal-title":"MOJ Women's Health"},{"issue":"8","key":"1448_CR11","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1089\/met.2016.0009","volume":"14","author":"A Gupta","year":"2016","unstructured":"Gupta A, Jakubowicz D, Nestler JE. Pioglitazone therapy increases insulin-stimulated release of d-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2016;14(8):391\u20136.","journal-title":"Metab Syndr Relat Disord"},{"issue":"5","key":"1448_CR12","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1007\/s13224-012-0183-3","volume":"62","author":"S Sangeeta","year":"2012","unstructured":"Sangeeta S. Metformin and pioglitazone in polycystic ovarian syndrome: a comparative study. J Obstet Gynaecol India. 2012;62(5):551\u20136. https:\/\/doi.org\/10.1007\/s13224-012-0183-3.","journal-title":"J Obstet Gynaecol India"},{"issue":"11","key":"1448_CR13","doi-asserted-by":"publisher","first-page":"CD003053","DOI":"10.1002\/14651858.CD003053.pub6","volume":"11","author":"LC Morley","year":"2017","unstructured":"Morley LC, Tang T, Yasmin E, Norman RJ, Balen AH. Insulin-sensitizing drugs (metformin, rosiglitazone, pioglitazone, d-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea, and subfertility. Cochrane Database Syst Rev. 2017;11(11):CD003053. https:\/\/doi.org\/10.1002\/14651858.CD003053.pub6.","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"1448_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.fertnstert.2007.01.117","volume":"90","author":"H Ota","year":"2008","unstructured":"Ota H, Goto T, Yoshioka T, Ohyama N. Successful pregnancies treated with pioglitazone in infertile patients with polycystic ovary syndrome. Fertil Steril. 2008;90(3):709\u201313.","journal-title":"Fertil Steril"},{"issue":"1","key":"1448_CR15","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.fertnstert.2009.02.029","volume":"94","author":"CH Kim","year":"2010","unstructured":"Kim CH, Jeon GH, Kim SR, Kim SH, Chae HD, Kang BM. Effects of Pioglitazone on ovarian stromal blood flow, ovarian stimulation, and in vitro fertilization outcome in patients with polycystic ovary syndrome. Fertil Steril. 2010;94(1):236\u201341.","journal-title":"Fertil Steril"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-021-01448-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-021-01448-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T09:02:55Z","timestamp":1629190975000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-021-01448-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,17]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1448"],"URL":"https:\/\/doi.org\/10.1186\/s12905-021-01448-5","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,17]]},"assertion":[{"value":"29 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mashhad University of medical sciences supervised this randomized clinical trial study from 2014 until 2017, and 61 PCOS patients who were referred to the Milad Infertility Center for the treatment of infertility were enrolled using a non-probabilistic sampling method. The Ethical Committee of Mashhad University of Medical Sciences approved the hold on \"March 15, 2014\" and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}